Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 9 | Arthritis Research & Therapy

Fig. 9

From: Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Fig. 9

Improvements reported in minimally clinically important difference (MCID) for health-assessment questionnaire-disability index (HAQ-DI), patient’s assessment of arthritic pain, patient’s global assessment of disease activity (PtGA), short form-36 physical component summary (SF-36 PCS) and fatigue in certolizumab pegol (CZP) intention-to-treat (a) and CZP completers (b). Data were assessed using mixed model repeated measures imputation. MCID was defined as a decrease of ≥0.22 points from baseline in HAQ-DI, improvements ≥2.5 in the SF-36 PCS score from baseline, and for fatigue, pain and PtGA ≥10-point decrease from baseline. Data are presented at week 36 and week 220 as timing of visits meant that data were not available for week 24 and week 232

Back to article page